By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Pfizer invests EUR 54 million in Austrian-based research

Pfizer building in Viennna © Pfizer

New medicines are being developed in cooperation with local medical universities, research institutions and hospitals. Clinical research carried out by Pfizer focuses on new treatments for cancer, chronic-inflammatory diseases, cardiovascular diseases, rare diseases, pain and new vaccines. In 2017 Pfizer also invested EUR 54 million in Austria.

One example of the company’s cooperation in the field of clinical research is its partnership with the academic institution ABCSG. The study group led by Prof. Michael Gnant (Medical University of Vienna) heads a registration trial with a substance developed by Pfizer to treat breast cancer. The study is completely financed by Pfizer and ABCSG is in charge of data, patient and project management in 21 countries across the globe. 5,600 patients are to take part in the study over a period of fifteen years. 18 hospitals and about 500 patients are involved just in Austria. „The fact that responsibility for a globally implemented Phase III study is in Austrian hands is a nice acknowledgement of the longstanding work done by ABCSG”, explains Prof. Gnant, President of ABCSG.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • AAIC - AI in AgriTech

    25.01.2022 - 26.01.2022, virtual

  • ROBOTICS Slovenia 2022

    15.02.2022 - 17.02.2022, Ljubljana, Slovenia

Austria Map

Find the perfect location for your company

We are lucky to benefit from a lot of reserach incentives here in Austria. We are very proud to be here as Austria is an ideal location for research.

TachoEASY Austria

Logo
More testimonials

news from the business location Austria

The path taken by immune cells

In order to combat infections and heal injuries as well as to fight against tumours, immune cells need to enter tissue.

IPCEI on Microelectronics – NXP Contributes Security Technology

Important Projects of Common European Interest (IPCEI) are large-scale innovation programmes in which several EU member states participate. They are designed to sustainably strengthen European value chains in critical technology sectors. Microelectronics comprises one such key technology. Within the context of the IPCEI on Microelectronics, NXP Gratkorn is focusing on the issue of “security,” thus contributing to Europe’s digital sovereignty and the resilience of its critical infrastructures.

More news All blog posts